VHCP Management II’s Akari Therapeutics AKTX Stock Holding History

VHCP Management II’s Portfolio AKTX Stock Details AKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-533	Closed	-$1.85M	–	18
2017 Q4	$1.85M	Hold	533	–	–	0.44%	16
2017 Q3	$2.62M	Hold	533	–	–	0.72%	14
2017 Q2	$1.97M	Buy	533 +71	+15%	+$561K	0.78%	13
2017 Q1	$4.09M	Hold	462	–	–	1.67%	11
2016 Q4	$2.6M	Hold	462	–	–	1.25%	16
2016 Q3	$3.14M	Hold	462	–	–	1.61%	17
2016 Q2	$4.98M	Hold	462	–	–	3.01%	11
2016 Q1	$5.17M	Hold	462	–	–	3.4%	10
2015 Q4	$5.36M	Buy	+462	New	+$6.86M	4.4%	9

Other funds holding AKTX

Hikari Power Tokyo, Japan $1.15B AUM 5.31% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

ECM

Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

Parallax Volatility Advisers San Francisco, California $38.6B AUM 45.89% 1-Year Est. Return

IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return

VHCP Management II's AKTX Position: Q1 2018 in Review

VHCP Management II sold out of Akari Therapeutics (AKTX) in Q1 2018, closing a stake of 533 shares — an estimated $1.85M sold.

VHCP Management II first reported a position in AKTX in Q4 2015 and held it in 9 quarters. The position peaked at $5.36M in Q4 2015. 9 funds tracked by Wall St. Rank hold AKTX as of Q1 2018.

VHCP Management II reported no remaining Akari Therapeutics position as of Q1 2018 after selling out during the quarter.
VHCP Management II sold 533 Akari Therapeutics shares in Q1 2018, an estimated $1.85M.
VHCP Management II first reported a position in Akari Therapeutics in Q4 2015 and held it in 9 quarters.
VHCP Management II's Akari Therapeutics position peaked at $5.36M in Q4 2015.
9 funds tracked by Wall St. Rank held Akari Therapeutics as of Q1 2018.

Based on VHCP Management II's 13F filing for Q1 2018, filed 14 May 2018.